ITUS CORPORATION (NASDAQ:ITUS) Files An 8-K Other Events
Item 8.01         Other Items.

On April 10, 2017, the Securities and Exchange Commission declared effective ITUS Corporation’s (the “Company”) Registration Statement on Form S-3 (No. 333-217060) for the resale by certain security holders of the Company, including Meetrix Communications, Inc. (“Meetrix”), of up to 1,487,606 shares of common stock (including 500,000 shares of common stock issuable upon exercise of certain outstanding warrants). Of the 1,487,606 shares registered for resale, 947,606 shares were issued to Meetrix in payment of an obligation of the Company equal to approximately $4.8 million. With the completion of the payment of this obligation, and taking into account the proceeds received by the Company in its recently completed rights offering, the Company believes that, as of the date of this Current Report, the Company has shareholders’ equity of approximately $3.6 million.

Cautionary Note Regarding Forward-Looking Statements

This Current Report contain forward-looking statements. Statements that are not historical fact may be considered forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements are not statements of historical facts, but rather reflect the Company’s current expectations concerning future events and results. We generally use the words “believes,” “expects,” “intends,” “plans,” “anticipates,” “likely,” “will” and similar expressions to identify forward-looking statements. Such forward-looking statements (including those concerning our level of shareholders’ equity), involve risks, uncertainties and other factors, some of which are beyond our control, which may cause our actual or reported results, performance or achievements, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. These risks, uncertainties and factors include, but are not limited to, those factors set forth in “Item 1A – Risk Factors” and other sections of our Annual Report on Form 10-K for the fiscal year ended October 31, 2016 as well as in our Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. We undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

 
 
 
 
 

 About ITUS CORPORATION (NASDAQ:ITUS) 

ITUS Corporation is engaged in developing a diagnostic platform called Cchek, for the early detection of tumor-based cancers. The Cchek cancer detection platform measures a patient's immune response to a malignancy by detecting the presence, absence and quantity of certain immune cells that exist in and around a tumor and that enter the blood stream. Instead of seeking to alter or boost the body's immune system and its ability to destroy cancer cells, the Company has developed techniques and protocols for measuring the subtle immunological changes that occur in the blood stream during tumor development. Through its protocols, the Company has detected the biomarkers in the peripheral blood of biopsy verified cancer patients, and in distinguishing the blood of healthy patients from the blood of cancer patients.
	
ITUS CORPORATION (NASDAQ:ITUS) Recent Trading Information 

ITUS CORPORATION (NASDAQ:ITUS) closed its last trading session up +0.02 at 2.30 with 16,458 shares trading hands.